Surgical Oncology Service, Department of General Surgery, Wake Forest Baptist Health, Winston-Salem, NC, USA.
Wake Forest School of Medicine, Winston-Salem, NC, USA.
Ann Surg Oncol. 2018 Mar;25(3):667-673. doi: 10.1245/s10434-017-6293-5. Epub 2017 Dec 19.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has dramatically improved the survival of patients with epithelioid peritoneal mesothelioma. It is unknown if CRS/HIPEC is indicated for the more aggressive biphasic mesothelioma variant.
A retrospective analysis of the Peritoneal Surface Oncology Group International (PSOGI) registry including data from 33 centers was performed. Survival was reviewed based on mesothelioma type, completion of cytoreduction, and volume of disease.
Overall, 484 of 1165 (41.5%) CRS/HIPEC procedures with complete CC0 and CC1 cytoreductions were analyzed; 450 (93%) procedures were performed for epithelioid mesotheliomas, while 34 (7%) were performed for biphasic mesotheliomas. For patients with CC0 resection, 5-year survival was 64.5 and 50.2% (median 7.8 and 6.8 years; p = 0.015) for epithelioid and biphasic mesotheliomas, respectively, while inclusion of CC1 resections in the analysis resulted in inferior 5-year survival of 62.9% and 41.6% (median 7.8 and 2.8 years; p = 0.0012), respectively. Incomplete CC2 resections for biphasic primaries resulted in a median survival of 4.3 months. Univariate analysis of the biphasic cohort indicated Peritoneal Cancer Index (PCI; p = 0.015), CC status of resection (p < 0.0001), and Ki67 (p = 0.04) as predictors of survival. Systemic chemotherapy before (p = 0.55) or after (p = 0.7) CRS/HIPEC did not influence survival. In multivariate analysis, only PCI (p = 0.03) and CC (p = 0.04) remained significant.
Long-term survival is achievable in patients with low-volume biphasic mesothelioma after complete macroscopic cytoreduction. Biphasic peritoneal mesotheliomas should not be considered as an absolute contraindication for CRS/HIPEC if there is low-volume disease and if complete cytoreduction can be achieved.
细胞减灭术和腹腔内热灌注化疗(CRS/HIPEC)显著提高了上皮样腹膜间皮瘤患者的生存率。目前尚不清楚 CRS/HIPEC 是否适用于侵袭性更强的双相间皮瘤变体。
对腹膜表面肿瘤国际组织(PSOGI)登记处的 33 个中心的数据进行了回顾性分析。根据间皮瘤类型、细胞减灭术的完成情况和疾病体积对生存率进行了回顾性分析。
总体而言,对 1165 例 CRS/HIPEC 手术中完全 CC0 和 CC1 细胞减灭术的 484 例(41.5%)进行了分析;450 例(93%)手术用于上皮样间皮瘤,34 例(7%)用于双相间皮瘤。对于 CC0 切除的患者,5 年生存率分别为上皮样和双相间皮瘤的 64.5%和 50.2%(中位数分别为 7.8 和 6.8 年;p=0.015),而将 CC1 切除纳入分析后,5 年生存率分别为 62.9%和 41.6%(中位数分别为 7.8 和 2.8 年;p=0.0012)。对于双相性原发性不完全 CC2 切除术,中位生存期为 4.3 个月。双相组的单因素分析表明,腹膜癌指数(PCI;p=0.015)、切除的 CC 状态(p<0.0001)和 Ki67(p=0.04)是生存的预测因素。CRS/HIPEC 前后(p=0.55)的全身化疗均未影响生存率。多因素分析中,只有 PCI(p=0.03)和 CC(p=0.04)仍然具有显著意义。
在完全肉眼减瘤后,低体积双相间皮瘤患者可实现长期生存。如果疾病体积低且可以实现完全细胞减灭术,不应将双相腹膜间皮瘤视为 CRS/HIPEC 的绝对禁忌证。